IPP Bureau
SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
By IPP Bureau - August 21, 2025
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders
By IPP Bureau - August 20, 2025
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Foxconn invests US$30 million in Robocore to expand into elderly care robotics market
By IPP Bureau - August 20, 2025
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial
By IPP Bureau - August 19, 2025
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair
By IPP Bureau - August 19, 2025
Alembic receives USFDA final approval for Macitentan Tablets, 10 mg
By IPP Bureau - August 19, 2025
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
Novo Nordisk's Wegovy approved in the US for the treatment of MASH
By IPP Bureau - August 19, 2025
The accelerated approval is supported by results from part 1 of the ESSENCE trial
FDA approves first immunotherapy for recurrent respiratory papillomatosis
By IPP Bureau - August 19, 2025
Tonix receives FDA approval of Tonmya for treatment of fibromyalgia
By IPP Bureau - August 19, 2025
Sarepta advances siRNA collaboration and sale of arrowhead equity investment
By IPP Bureau - August 19, 2025
Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
BioAge Labs doses first patient in BGE-102 phase 1 trial
By IPP Bureau - August 19, 2025
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Pfizer’s sickle cell disease candidate fails Phase III trial
By IPP Bureau - August 19, 2025
Inclacumab was generally well tolerated in THRIVE-131
Shanmuga Hospital commissions advanced PH impedance and manometry system
By IPP Bureau - August 18, 2025
This system enables comprehensive diagnosis of both acid and non-acid reflux, along with esophageal motility disorders.
Kwality Pharma receives product registration of Bleomycin 15 IU per vial in Mexico
By IPP Bureau - August 18, 2025
The projected business potential is around US$ 1 million in the first year
Merck and mantro launch EdiMembre to transform alternative protein industry
By IPP Bureau - August 18, 2025
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
